3.89
0.08 (2.10%)
| Previous Close | 3.81 |
| Volume | 1,297,322 |
| Price / Sales | 3.10 |
| Price / Book | 24.24 |
| 52 Weeks Range |
| Profit Margin | -16.11% |
| Operating Margin (TTM) | -466.29% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | 4,900.00% |
| Total Debt/Equity (MRQ) | 30.33% |
| Current Ratio (MRQ) | 11.00 |
| Operating Cash Flow (TTM) | -20.48 M |
| Levered Free Cash Flow (TTM) | -9.60 M |
| Return on Assets (TTM) | -6.10% |
| Return on Equity (TTM) | -6.91% |
News Mood
-
ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
06 Nov, 5:16AM
AIStockmoo Score
| Value 30% | -0.1 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -3.7 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Price and its moving averages are lined up in a downtrend. Its main moving average is falling. Close to its falling moving average. Volume is heavier on up days. Below its long-term moving average, so not rated positive. info | |
| Candle Patterns info | NA |
| Below its medium-term trend line. info | |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | -3.3 |
| Insider Activity info | NA |
| Institutions net -7.54% of shares in their latest 13F filings: 107 holders increased, 97 decreased (quarter to 30 Sep 2026). info | |
| Short interest -18.2% from 31 Aug to 30 Oct 2026, 11.1 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Short-term trend up, medium and long-term down. Short-term decline easing. info | |
| Price is near resistance. Levels trending up. info | |
| Final Score | -2.49 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ARS Pharmaceuticals, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| SPRY | - | - | - | 24.24 |
| TRML | 1 B | - | - | 4.76 |
| OBIO | - | - | - | 57.25 |
| VRDN | - | - | - | 7.26 |
| VRCA | - | - | - | 15.60 |
| TECH | - | 0.44% | - | 5.28 |
Select this tab to load the latest available analysis.
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.93% |
| % Held by Institutions | 80.28% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 91.55%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 107 | 9,397,041 |
| Decreased | 97 | 16,447,542 |
| New | 38 | 2,967,760 |
| Sold out | 40 | 3,536,660 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 18,990,650 | 11.1 |
| 15 Oct 2026 | 19,819,885 | 12.6 |
| 30 Sep 2026 | 21,190,047 | 16.1 |
| 15 Sep 2026 | 23,073,209 | 15.5 |
| 31 Aug 2026 | 23,209,349 | 14.1 |
| 14 Aug 2026 | 22,952,291 | 11.0 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
ARS Pharmaceuticals Inc (SPRY) posted 42% year-over-year growth in neffy end-user demand and cut SG&A by over 40%, keeping it on track for cash flow breakeven by year-end 2027… |
| 05 Nov 2026 | Yahoo Finance |
ARS Pharmaceuticals Q3 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027. President and CEO Donn Casale said neffy’s share of the U.S. epinephrine ma… |
| 05 Nov 2026 | Yahoo Finance |
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -5.88% and -11.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 05 Nov 2026 | Yahoo Finance |
ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy® neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted provider commercial strategyReduced SG&A spend reflected in Q3 operating… |
| 29 Oct 2026 | Yahoo Finance |
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
ARS Pharma to Report Third Quarter 2026 Financial Results
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and… |
| 01 Sep 2026 | Yahoo Finance |
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in… |
| 21 Aug 2026 | Yahoo Finance |
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous… |
| 20 Aug 2026 | Yahoo Finance |
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the… |
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |